News

End of the line for Swiss IPO
Enlarge image

PoliticsSwitzerland

End of the line for Swiss IPO

23.10.2014 - Just one day before its planned initial listing, Swiss Molecular Partners has cancelled its IPO. The reason: "unfavourable market conditions".

It was supposed to be the first biotech going public on the Swiss Exchange since 2009. But now, Schlieren-based Molecular Partners AG has announced that it is postponing its IPO – indefinitely. Initially, the Swiss company was hoping to bring in €145m, with each share costing between CHF28-35 (€23-29). This would have priced the company’s total worth at €500m. Now, however, the plans are off the table.

Although the company is not ruling out another IPO attempt at a later date, it is now focussing on the further development of their product pipeline. Molecular Partners specialises in protein-based drugs, so-called DARPins for the treatment of eye disease and cancer. These protein therapeutics that are derived from the protein Ankyrin can bind antigenes, similar to antibodies. Together with US partner Allergan, the biotech is developing its most advanced product candidate, Abicipar, for the treatment of wet AMD.

So far, Molecular partners has been financed by venture capitalists Essex Woodlands, Index Ventures, Johnson & Johnson Development Corporation, BB Biotech Ventures and Endeavour Vision. In addition to €46m in venture capital, the company also collected €133m in payments from partnerships.


© european-biotechnology-news.com/um

http://www.european-biotechnology-news.com/news/news/2014-04/game-over-for-swiss-ipo.html

PoliticsEU

23.10.2014 Jean-Claude Juncker can breathe a sigh of relief as MEPs voted “yes” by a large majority to his team of European Union Commissioners. Previous to the vote, Juncker had shifted the EMA back to the health commissioner in response to protests.

FinancingFrance

21.10.2014 Yet another European company is looking for money on the US stock exchange – French DBV Technologies SA is all set up for its secondary listing on NASDAQ. The French biotech company hopes to rake in US$98m for its peanut allergy patches.

FinancingDenmark

18.10.2014 After raising US$220.5m (€172m) with its IPO, fast Forward Pharma’s lucky streak hits an obstacle on the road to success with shares falling 17% on its first day of trading.

M&AUKItaly

17.10.2014 Abandoned at the altar: Abbvie has dropped plans to acquire UK’s Shire following new US tax rules. This puts a stop to one of the biggest pharma mergers planned this year.

FinancingUKBelgium

15.10.2014 Bicycle Therapeutics wins €25m backing by major pharma venture capitalists for the development of a new class of oncology drugs.

FinancingGermanySwitzerlandNetherlands

13.10.2014 Biotechnology IPOs are back in fashion – German Probiodrug AG wants to raise €32m with its IPO, whilst Swiss Molecular Partners AG hopes the launch of its IPO will gain a revenue of €145m.

BusinessIreland

10.10.2014 Actavis has announced plans to merge with American pharma company Durata - a move that will strengthen their infectious diseases portfolio.

RegulationEU

07.10.2014 In an unprecedented move, the European Medicines Agency has approved a system allowing the future analysis of clinical trial data.

FinanceNetherlandsEU

06.10.2014 Another fund from the Netherlands has raised €92m in its first close and will invest the money in companies developing innovative therapeutics, medical devices and diagnostics.

© 2007-2014 BIOCOM

http://www.european-biotechnology-news.com/news/news.html

Events

All Events

Current issue

All issues

Product of the week

Products

Stock list

All quotes

TOP

  • VITA 344.32 EUR6.67%
  • MORPHOSYS74.44 EUR4.04%
  • STRATEC BIOMEDICAL39.84 EUR3.94%

FLOP

  • CYTOS0.16 CHF-5.88%
  • CO.DON2.75 EUR-3.17%
  • ADDEX3.30 CHF-2.94%

TOP

  • BIOFRONTERA2.90 EUR31.2%
  • VITA 344.32 EUR8.0%
  • BB BIOTECH157.70 EUR7.3%

FLOP

  • PAION2.24 EUR-30.0%
  • CYTOS0.16 CHF-27.3%
  • MAGFORCE5.90 EUR-17.5%

TOP

  • SANTHERA85.50 CHF2335.9%
  • CO.DON2.75 EUR192.6%
  • PAION2.24 EUR163.5%

FLOP

  • CYTOS0.16 CHF-95.8%
  • THERAMETRICS0.08 CHF-42.9%
  • 4SC0.97 EUR-42.6%

No liability assumed, Date: 23.10.2014